Free Trial

Apogee Therapeutics (APGE) Short Interest Ratio & Short Volume

Apogee Therapeutics logo
$47.25 -3.76 (-7.37%)
(As of 11/15/2024 ET)

Apogee Therapeutics Short Interest Data

Apogee Therapeutics (APGE) has a short interest of 6.81 million shares, representing 18.87% of the float (the number of shares available for trading by the public). This marks a -0.87% decrease in short interest from the previous month. The short interest ratio (days to cover) is 17.3, indicating that it would take 17.3 days of the average trading volume of 364,184 shares to cover all short positions.

Current Short Interest
6,810,000 shares
Previous Short Interest
6,870,000 shares
Change Vs. Previous Month
-0.87%
Dollar Volume Sold Short
$354.39 million
Short Interest Ratio
17.3 Days to Cover
Last Record Date
October 31, 2024
Outstanding Shares
45,030,000 shares
Float Size
36,090,000 shares
Short Percent of Float
18.87%
Today's Trading Volume
526,903 shares
Average Trading Volume
364,184 shares
Today's Volume Vs. Average
145%
Short Selling Apogee Therapeutics?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Apogee Therapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

APGE Short Interest Over Time

APGE Days to Cover Over Time

APGE Percentage of Float Shorted Over Time

Apogee Therapeutics Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
10/31/20246,810,000 shares $354.39 million -0.9%18.9%17.3 $52.04
10/15/20246,870,000 shares $377.03 million -5.0%18.9%17.4 $54.88
9/30/20247,230,000 shares $424.69 million -11.7%19.9%17.1 $58.74
9/15/20248,190,000 shares $420.80 million -1.1%22.6%17.8 $51.38
8/31/20248,280,000 shares $423.69 million +1.1%22.8%18.6 $51.17
8/15/20248,190,000 shares $371.01 million +5.3%22.0%18.5 $45.30
7/31/20247,780,000 shares $378.89 million -9.6%21.1%16.5 $48.70
7/15/20248,610,000 shares $425.16 million +8.4%23.4%18.9 $49.38
6/30/20247,940,000 shares $312.44 million +18.0%21.4%17.4 $39.35
6/15/20246,730,000 shares $276.87 million +3.5%18.2%14.4 $41.14
5/31/20246,500,000 shares $296.66 million +36.0%17.6%11.3 $45.64
5/15/20244,780,000 shares $254.77 million -1.2%12.3%6.7 $53.30
4/30/20244,840,000 shares $243.45 million +6.4%14.0%7.2 $50.30
4/15/20244,550,000 shares $241.47 million -1.1%13.0%6.6 $53.07
3/31/20244,600,000 shares $305.67 million +50.8%13.1%6.8 $66.45
3/15/20243,050,000 shares $208.35 million -2.6%9.8%4.8 $68.31
2/29/20243,130,000 shares $108.99 million -5.2%14.6%6.1 $34.82
2/15/20243,300,000 shares $117.94 million -12.0%15.4%9.9 $35.74
1/31/20243,750,000 shares $125.63 million No Change17.6%11.4 $33.50

APGE Short Interest - Frequently Asked Questions

What is Apogee Therapeutics' current short interest?

Short interest is the volume of Apogee Therapeutics shares that have been sold short but have not yet been closed out or covered. As of October 31st, investors have sold 6,810,000 shares of APGE short. 18.87% of Apogee Therapeutics' shares are currently sold short. Learn More on Apogee Therapeutics' current short interest.

What is a good short interest ratio for Apogee Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. APGE shares currently have a short interest ratio of 17.0. Learn More on Apogee Therapeutics's short interest ratio.

Which institutional investors are shorting Apogee Therapeutics?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Apogee Therapeutics: Jane Street Group LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Apogee Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 18.87% of Apogee Therapeutics' floating shares are currently sold short.

Is Apogee Therapeutics' short interest increasing or decreasing?

Apogee Therapeutics saw a decline in short interest in October. As of October 31st, there was short interest totaling 6,810,000 shares, a decline of 0.9% from the previous total of 6,870,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Apogee Therapeutics' float size?

Apogee Therapeutics currently has issued a total of 45,030,000 shares. Some of Apogee Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Apogee Therapeutics currently has a public float of 36,090,000 shares.

How does Apogee Therapeutics' short interest compare to its competitors?

18.87% of Apogee Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Apogee Therapeutics: Qiagen (1.61%), Revolution Medicines, Inc. (10.78%), Intra-Cellular Therapies, Inc. (2.23%), Roivant Sciences Ltd. (12.38%), Viking Therapeutics, Inc. (11.92%), Ascendis Pharma A/S (5.62%), Legend Biotech Co. (8.70%), Elanco Animal Health Incorporated (2.81%), Cytokinetics, Incorporated (13.75%), Blueprint Medicines Co. (6.50%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks.

What does it mean to sell short Apogee Therapeutics stock?

Short selling APGE is an investing strategy that aims to generate trading profit from Apogee Therapeutics as its price is falling. APGE shares are trading down $3.76 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Apogee Therapeutics?

A short squeeze for Apogee Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of APGE, which in turn drives the price of the stock up even further.

How often is Apogee Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including APGE, twice per month. The most recent reporting period available is October, 31 2024.




This page (NASDAQ:APGE) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners